Clemént O, Mühler A, Vexler V S, Kuwatsuru R, Berthezène Y, Rosenau W, Brasch R C
Department of Radiology, University of California, San Francisco 94143-0628.
J Magn Reson Imaging. 1993 Jan-Feb;3(1):71-7. doi: 10.1002/jmri.1880030113.
A new hepatobiliary contrast agent for magnetic resonance (MR) imaging, gadolinium-ethoxybenzyl (EOB)-diethylemetriaminepentaacetic acid (DTPA), was compared with Gd-DTPA to define the potential for improving tumor-liver contrast in a rodent liver adenocarcinoma model. With a T1-weighted spin-echo sequence, the contrast-to-noise ratio (C/N) for tumor before contrast agent administration was 5 (arbitrary units), the tumor appearing slightly hypo-intense with respect to liver parenchyma. After Gd-DTPA injection (0.1 mmol/kg), tumor enhanced more strongly than liver, resulting in an equalization of tumor and liver signal intensities and a decline in C/N to zero at 3 minutes after injection. After Gd-EOB-DTPA injection (0.1 mmol/kg), liver enhanced more strongly than tumor. Five minutes after injection, C/N increased from 5 to 25 and remained above 17 for 50 minutes. The data indicate that Gd-EOB-DTPA yields higher and more prolonged tumor-liver contrast than Gd-DTPA on T1-weighted spin-echo images. The high liver-tumor contrast after Gd-EOB-DTPA administration should prove clinically advantageous for MR imaging detection of focal hepatic masses.
一种用于磁共振（MR）成像的新型肝胆造影剂钆-乙氧基苄基（EOB）-二乙三胺五乙酸（DTPA），与钆喷酸葡胺（Gd-DTPA）进行了比较，以确定在啮齿动物肝腺癌模型中改善肿瘤与肝脏对比度的潜力。使用T1加权自旋回波序列，在注射造影剂前肿瘤的对比噪声比（C/N）为5（任意单位），相对于肝实质，肿瘤表现为轻度低信号。注射Gd-DTPA（0.1 mmol/kg）后，肿瘤比肝脏强化更明显，导致肿瘤和肝脏信号强度相等，注射后3分钟C/N降至零。注射钆-乙氧基苄基二乙三胺五乙酸（Gd-EOB-DTPA，0.1 mmol/kg）后，肝脏比肿瘤强化更明显。注射后5分钟，C/N从5增加到25，并在50分钟内保持在17以上。数据表明，在T1加权自旋回波图像上，Gd-EOB-DTPA比Gd-DTPA产生更高且更持久的肿瘤-肝脏对比度。Gd-EOB-DTPA给药后高的肝脏-肿瘤对比度在磁共振成像检测局灶性肝肿块方面应具有临床优势。
